Investigation of Potency and Safety of Live-Attenuated Peste des Petits Ruminant Virus Vaccine in Goats by Detection of Cellular and Humoral Immune Response

Milovanović, Milovan; Dietze, Klaas; Wernery, Ulrich; Hoffmann, Bernd

doi:10.3390/v15061325

Cited by 2 publications

(2 citation statements)

References 35 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is not possible to say from the study presented here whether the absence of live excreted virus was due to the pre-neutralisation of virus particles by circulating anti-H antibody, or to an absence of whole virus particles, with the detected viral RNA reflecting cell debris from infected cells. There is probably a minimum level of virus that must be circulating in infected animals in order for live virus to be excreted: a recent study 38 using modern RT-qPCR detection methods have detected viral RNA in blood and swabs of animals following vaccination with the live attenuated Nigeria/75 vaccine strain of PPRV, at similar levels to that found in this study in single-vaccinated animals following challenge, even though the live attenuated PPRV vaccine strain has never been reported as being excreted.…”

Section: Discussionmentioning

confidence: 99%

Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein

Darpel,

Corla,

Stedman

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

A recombinant, replication-defective, adenovirus-vectored vaccine expressing the H surface glycoprotein of peste des petits ruminants virus (PPRV) has previously been shown to protect goats from challenge with wild-type PPRV at up to 4 months post vaccination. Here, we present the results of a longer-term trial of the protection provided by such a vaccine, challenging animals at 6, 9, 12 and 15 months post vaccination. Vaccinated animals developed high levels of anti-PPRV H protein antibodies, which were virus-neutralising, and the level of these antibodies was maintained for the duration of the trial. The vaccinated animals were largely protected against overt clinical disease from the challenge virus. Although viral genome was intermittently detected in blood samples, nasal and/or ocular swabs of vaccinated goats post challenge, viral RNA levels were significantly lower compared to unvaccinated control animals and vaccinated goats did not appear to excrete live virus. This protection, like the antibody response, was maintained at the same level for at least 15 months after vaccination. In addition, we showed that animals that have been vaccinated with the adenovirus-based vaccine can be revaccinated with the same vaccine after 12 months and showed an increased anti-PPRV antibody response after this boost vaccination. Such vaccines, which provide a DIVA capability, would therefore be suitable for use when the current live attenuated PPRV vaccines are withdrawn at the end of the ongoing global PPR eradication campaign.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein

Darpel,

Corla,

Stedman

et al. 2024

npj Vaccines

View full text Add to dashboard Cite

show abstract

“…The N-speci c antibodies detected by the employed cELISA are not neutralizing antibodies. Nonetheless, they are considered indicators of an ongoing T-cell mediated immune response [53]. Evaluation of antibody responses following PPR vaccination using virus neutralization test (VNT), Hantigen-speci c antibodies cELISA which are neutralizing antibodies [55] or N-antigen-speci c antibodies cELISA and challenge studies reported no discrepancy between sero-conversion and protection [51; 52; 53].…”

Section: Discussionmentioning

confidence: 99%

Sero-prevalence of peste des petits ruminants virus-specific antibodies in Sudanese sheep and goats before and after vaccination

Algezoli,

Kamal,

Raouf

et al. 2024

Preprint

View full text Add to dashboard Cite

Peste des petits ruminants virus (PPRV) antibodies were studied in Sudanese sheep and goats (n = 855) before and after vaccination with a locally produced Nigeria 75/1 vaccine using a commercial competitive ELISA (cELISA) kit (IDvet Grabels). Animals were kept healthy under field conditions, in four states; Blue Nile (n = 250), North Kordofan (n = 189), South Darfur (n = 225) and the Northern State (n = 191). Before vaccination, sero-prevalence of PPRV antibodies was 54.6% (53.2%-56% 95% CI); high (64.8%-76.4% 95% CI) in South Eastern Sudan (Blue Nile), medium (50.5%-61.9% 95% CI) in Western Sudan (North Kordofan and South Darfur) and low (28.6%-35.2% 95% C.I) in Northern Sudan (Northern State). In high-risk areas (high sero-prevalence), Blue Nile (70.4%) and North Kordofan (57.7%), middle age groups (7–12 and 13–18 months) were identified as high-risk age. Middle age groups showed lower sero-prevalence than preceding (3–6 months) and subsequent (> 18 months) age groups while the risk of exposure increased with age. Current and previous findings suggested a transmission pathway of PPRV involving the South Eastern border (Blue Nile) and neighbouring Central Sudan to North Kordofan. One month after vaccination 88.4% (343/388) of sero-negative animals were sero-converted suggesting the efficacy of the locally produced Nigeria 75/1 vaccine. Had only the high- risk age group (7–18 months) was vaccinated, the overall population immunity (OPI) in high-risk areas (Blue Nile and North Kordofan) would have surpassed the threshold of 70% indicated for blocking PPRV transmission. However, lower vaccination coverage is expected in wider vaccination programme. findings justified targeting PPR control in Sudan, primarily, by vaccination of high-risk age groups in high-risk areas.

show abstract

Investigation of Potency and Safety of Live-Attenuated Peste des Petits Ruminant Virus Vaccine in Goats by Detection of Cellular and Humoral Immune Response

Cited by 2 publications

References 35 publications

Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein

Long-term trial of protection provided by adenovirus-vectored vaccine expressing the PPRV H protein

Sero-prevalence of peste des petits ruminants virus-specific antibodies in Sudanese sheep and goats before and after vaccination

Contact Info

Product

Resources

About